Is the Treatment of Hodgkin’s Disease Detrimental to the Parathyroid Gland?

Miltényi, Zsófia; Keresztes, Katalin; Lakos, Gabriella; Váróczy, László; Miltényi, L; Illés, Árpád

doi:10.1159/000079726

Cited by 3 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the data from the Childhood Cancer Survivor Study, hypothyroidism was the most common disturbance with a relative risk of 17.1; the relative risk of thyroid nodules compared to a sibling was 27 and thyroid cancer 18 (Sklar et al, 2000). We found no abnormality of calcium homeostasis, suggesting that the parathyroid glands are relatively resistant to radiation-induced damage, consistent with previous reports (Miltenyi et al, 2004). We have screened patients treated with mantle radiotherapy as part of a national recall for breast cancer screening.…”

Section: Discussionsupporting

confidence: 90%

High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening

et al. 2006

View full text Add to dashboard Cite

Assessment of late effects in a cohort of female Hodgkin's lymphoma patients treated with mantle radiotherapy, identified from the DoH breast cancer screening recall showed high mortality and frequent undiagnosed abnormalities in tissues affected by radiotherapy. With increasing age, this patient group may suffer premature cardiac and respiratory morbidity. (Henry-Amar and Joly, 1996). Current treatment usually involves multiagent chemotherapy combined with limited field radiotherapy in selected patients. However, until recently, the standard radiotherapy regimen for supradiaphragmatic HL was the mantle field (Deniz et al, 2003;Horwich and Swerdlow, 2004).Young women who received mantle radiotherapy are at increased risk of breast cancer (Swerdlow et al, 2000;Deniz et al, 2003;Travis et al, 2003;Horwich and Swerdlow, 2004;Kenney et al, 2004). The risk is proportional to radiation dose, and time from treatment (Hancock et al, 1993a;Wolden et al, 1998). Younger age at the time of treatment gives the greatest risk (Hancock et al, 1993a;Bhatia et al, 1996). At 25 years of follow-up, the cumulative risk of breast cancer for women treated between 10 and 19 years of age is reported as 15 -33%, and for those treated between the ages 20 and 29 years, 15 -25% (Horwich and Swerdlow, 2004). In 2003, the UK Department of Health launched a 'Patient Notification Exercise' to inform patients of the increased breast cancer risk. The exercise mandated recall of all women with HL, who were diagnosed at or below the age of 35 from 1962 onwards. Mantle radiotherapy is associated with other long-term complications including second malignancies, and disorders of the thyroid, heart and lung (Morgan et al, 1985;Gustavsson et al, 1990;Allavena et al, 1992;Gustavsson et al, 1992; Henry-Amar and Joly, 1996). The aim of our study was to investigate the incidence of late effects in women recalled in the UK 'Patient Notification Exercise'. MATERIALS AND METHODSPatients were identified from a network database, according to the following criteria: diagnosis of HL after 1962 and before the age of 35 years, and mantle radiotherapy. Women with a known history of breast cancer were excluded. Patients were offered a clinic appointment for counselling regarding breast cancer risk. Patients who accepted were asked if they were willing to participate in a study of late effects. The study was approved by the South Sheffield Research Ethics Committee and all patients gave written informed consent. Late effects study protocolPatients underwent a clinical evaluation including examination of the skin and thyroid. In addition, the following investigations were performed:Blood: Serum thyroid-stimulating hormone (TSH), free T4 (fT4), parathyroid hormone and corrected calcium. Cardiac: Echocardiogram and electrocardiogram. Respiratory: Spirometry and diffusion capacity (TLCO). Measurement and interpretation of resultsSerum measurements were considered against the laboratory normal range. Spirometry and transfer factors results were expressed as the percentage...

show abstract

Section: Discussionsupporting

confidence: 90%

High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Внешнее облучение шеи также рассматривается как этиологический фактор снижения ПТГ [ 17 ]. При этом считается, что лучевое поражение паращитовидных желез у больных ЛХ встречается гораздо реже, чем поражение ЩЖ [ 18 ].…”

Section: Discussionunclassified

“…В контрольную группу вошли 40 лиц без тяжелых хронических заболеваний, 24 женщины (включая 6 женщин в постменопаузе) и 16 мужчин, от 18 Клиническая картина у пациентов с манифестным гипотиреозом (n=12) была представлена отечным синдромом (n=6), диспепсическим синдромом (запоры, метеоризм и др., n=5), дислипидемией (n=10), нормохромной нормоцитарной анемией (n=4), у 4 женщин репродуктивного возраста отмечены нарушения цикла по типу олигоопсоменореи. Все больные данной группы имели избыточную массу тела или ожирение (медиана индекса массы тела 27,7 кг/м 2 ).…”

Section: этическая экспертизаunclassified

Endocrine disorders after combined chemoradiotherapy in Hodgkin Lymphoma survivors

Voytko

Климонтов

Поспелова

et al. 2023

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

BACKGROUND: Hodgkin’s lymphoma (HL) is one of the most common malignant lymphoproliferative diseases. Chemotherapy and radiotherapy used in the treatment of LH induce a number of toxic effects leading to dysfunction of endocrine system. Hormonal disorders in HL and their relationships with the therapy used remain to be clarified.AIM: To assess disorders of the endocrine function of thyroid, parathyroid glands and gonads in HL survivors.MATERIALS AND METHODS: Screening of endocrine dysfunction of the thyroid, parathyroid glands and gonads was performed in 160 adult patients with HL, 55 men and 105 women, at remission stage induced by chemotherapy or chemoradiotherapy. Forty healthy subjects, matched by age, were acted as control. The levels of TSH, T3, free T4, PTH, FSH, LH, free testosterone, dehydroepiandrosterone sulfate (DHEA-S), and sex-hormone binding globulin (SHBG) were measured in blood serum by ELISA. Bone mineral density (BMD) was assessed by DEXA.RESULTS: Hypothyroidism (25%), hyperparathyroidism (15.6%) and hypogonadism (29% of men and 25.3% of women) were the most prevalent endocrine disorders in LH survivors. Hypothyroidism was significantly more common in patients after chemoradiotherapy than in those who received only chemotherapy (χ2=9.4, р=0.002). In patients with hyperparathyroidism, there were negative correlations between PTH levels and BMD in the lumbar spine (r=-0.74, p=0.00002) and in the femoral neck (r=-0.66, p=0.0003). Men with HL demonstrated lower free testosterone concentrations when compared to control (p=0.04); LH and FSH levels were elevated (p=0.0004 and p=0.04, respectively). In men with HL the levels of DHEA-S were reduced (p=0.0009). The increased SHBG concentrations were revealed in 13 (23.6%) men. Women of reproductive age with HL had higher levels of LH in the luteal phase (p=0.05) and FSH in the follicular phase (p=0.02) than controls.CONCLUSION: The data indicate a high prevalence of the dysfunctions of thyroid, parathyroid glands, and gonads in HL survivors. Screening for endocrine disorders in these patients is highly recommended.

show abstract

Parathyroid Carcinoma, a Rare Cause of Hypercalcemia in a Patient With B-Cell Non-Hodgkinʼs Lymphoma

Halenka¹,

Klusová²,

Koranda³

et al. 2010

The Endocrinologist

View full text Add to dashboard Cite

Is the Treatment of Hodgkin’s Disease Detrimental to the Parathyroid Gland?

Cited by 3 publications

References 2 publications

High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening

High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening

Endocrine disorders after combined chemoradiotherapy in Hodgkin Lymphoma survivors

Parathyroid Carcinoma, a Rare Cause of Hypercalcemia in a Patient With B-Cell Non-Hodgkinʼs Lymphoma

Contact Info

Product

Resources

About